vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $164.7M, roughly 1.1× PTC THERAPEUTICS, INC.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -82.0%, a 83.6% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -22.7%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -11.5%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
PCRX vs PTCT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $164.7M |
| Net Profit | $2.9M | $-135.0M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | -43.3% |
| Net Margin | 1.6% | -82.0% |
| Revenue YoY | 5.0% | -22.7% |
| Net Profit YoY | — | -104.8% |
| EPS (diluted) | $0.07 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $164.7M | ||
| Q3 25 | $179.5M | $211.0M | ||
| Q2 25 | $181.1M | $178.9M | ||
| Q1 25 | $168.9M | $1.2B | ||
| Q4 24 | $187.3M | $213.2M | ||
| Q3 24 | $168.6M | $196.8M | ||
| Q2 24 | $178.0M | $186.7M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-135.0M | ||
| Q3 25 | $5.4M | $15.9M | ||
| Q2 25 | $-4.8M | $-64.8M | ||
| Q1 25 | $4.8M | $866.6M | ||
| Q4 24 | — | $-65.9M | ||
| Q3 24 | $-143.5M | $-106.7M | ||
| Q2 24 | $18.9M | $-99.2M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -43.3% | ||
| Q3 25 | 3.5% | 1.4% | ||
| Q2 25 | 4.7% | -19.5% | ||
| Q1 25 | 1.2% | 82.5% | ||
| Q4 24 | 13.2% | -76.2% | ||
| Q3 24 | -82.8% | -27.7% | ||
| Q2 24 | 15.9% | -21.5% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -82.0% | ||
| Q3 25 | 3.0% | 7.5% | ||
| Q2 25 | -2.7% | -36.3% | ||
| Q1 25 | 2.8% | 73.7% | ||
| Q4 24 | — | -30.9% | ||
| Q3 24 | -85.1% | -54.2% | ||
| Q2 24 | 10.6% | -53.1% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-1.63 | ||
| Q3 25 | $0.12 | $0.20 | ||
| Q2 25 | $-0.11 | $-0.83 | ||
| Q1 25 | $0.10 | $10.04 | ||
| Q4 24 | $0.38 | $-0.85 | ||
| Q3 24 | $-3.11 | $-1.39 | ||
| Q2 24 | $0.39 | $-1.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $-205.3M |
| Total Assets | $1.2B | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $1.9B | ||
| Q3 25 | $246.3M | $1.7B | ||
| Q2 25 | $445.9M | $2.0B | ||
| Q1 25 | $493.6M | $2.0B | ||
| Q4 24 | $484.6M | $1.1B | ||
| Q3 24 | $453.8M | $1.0B | ||
| Q2 24 | $404.2M | $1.1B |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-205.3M | ||
| Q3 25 | $727.2M | $-155.8M | ||
| Q2 25 | $757.8M | $-206.5M | ||
| Q1 25 | $798.5M | $-185.8M | ||
| Q4 24 | $778.3M | $-1.1B | ||
| Q3 24 | $749.6M | $-1.1B | ||
| Q2 24 | $879.3M | $-980.2M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $2.9B | ||
| Q3 25 | $1.3B | $2.6B | ||
| Q2 25 | $1.5B | $2.6B | ||
| Q1 25 | $1.6B | $2.7B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $1.6B | $1.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-34.3M |
| Free Cash FlowOCF − Capex | — | $-36.6M |
| FCF MarginFCF / Revenue | — | -22.3% |
| Capex IntensityCapex / Revenue | — | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-34.3M | ||
| Q3 25 | $60.8M | $-66.3M | ||
| Q2 25 | $12.0M | $-58.3M | ||
| Q1 25 | $35.5M | $870.1M | ||
| Q4 24 | $33.1M | $-30.0M | ||
| Q3 24 | $53.9M | $-77.0M | ||
| Q2 24 | $53.2M | $-71.5M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-36.6M | ||
| Q3 25 | $57.0M | $-69.7M | ||
| Q2 25 | $9.3M | $-59.6M | ||
| Q1 25 | $26.9M | $868.4M | ||
| Q4 24 | $31.0M | $-33.8M | ||
| Q3 24 | $49.8M | $-77.5M | ||
| Q2 24 | $51.6M | $-78.8M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -22.3% | ||
| Q3 25 | 31.7% | -33.1% | ||
| Q2 25 | 5.1% | -33.3% | ||
| Q1 25 | 15.9% | 73.8% | ||
| Q4 24 | 16.6% | -15.8% | ||
| Q3 24 | 29.6% | -39.4% | ||
| Q2 24 | 29.0% | -42.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 2.2% | 1.6% | ||
| Q2 25 | 1.5% | 0.7% | ||
| Q1 25 | 5.1% | 0.1% | ||
| Q4 24 | 1.1% | 1.8% | ||
| Q3 24 | 2.4% | 0.3% | ||
| Q2 24 | 0.9% | 4.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | -4.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | 1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PTCT
Segment breakdown not available.
